RxDoctor Payments Data

Carlos Podesta, MD

Cardiovascular Disease · Cookeville, TNNPI 1881099885

Payments from drug & device makers

$5,694in general payments, 2019–2025

Across 172 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Abbott$1K
  • Medtronic$490
  • Abiomed$428
  • Boston Scientific$315
  • Amgen$219
  • plus $2K from 16 others
$87in research payments, 2019–2025

Across 1 payment — averaging $87.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$87

What the payments were for

  • Travel & lodging$1,46826%
  • Food & beverage$4,22674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,694 in reported general payments places this provider in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$218,220
Medicare patients
999
Services billed
2,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$244,583
JardianceEmpagliflozin96$122,536
XareltoRivaroxaban82$102,301
Repatha SureclickEvolocumab130$81,583
EntrestoSacubitril/Valsartan37$56,261
Metoprolol Succinate381$7,327
Prasugrel Hcl19$3,993
Atorvastatin Calcium248$3,235
Rosuvastatin Calcium189$2,845
Isosorbide Mononitrate ErIsosorbide Mononitrate204$2,132
Flecainide Acetate36$1,832
Potassium Chloride97$1,799
Metoprolol Tartrate261$1,619
Amiodarone Hcl31$1,515
Ranolazine ErRanolazine22$1,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$244,583227 claims
Johnson & JohnsonXarelto$174$102,30182 claims
NovartisEntresto$102$56,26137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →